Upadacitinib is a JAK1-selective inhibitor indicated for autoimmune and inflammatory diseases.
We offer Upadacitinib API with high purity and well-controlled impurity profile, suitable for generic development.
Manufactured under China GMP.
DMF under preparation.
Available for R&D, clinical, and commercial supply.
Shandong Jikun Biopharmaceutical Co., Ltd., established in 2022, has a planned floor area of 50,000 m? and is located in a provincial - level chemical industrial park in Shandong, China. Integrating the R & D, production, and domestic and foreign trade sales of medical devices, new materials, active pharmaceutical ingredients, pharmaceutical intermediates.
It can efficiently undertake the whole - process services such as process R & D, process optimization, and product customization from the laboratory to scale - up production.
Upholding the vision of "Health and Beauty Go Hand in Hand", Shandong Jikun spares no effort to provide customers with high - value services and continuously contributes to a healthy and beautiful life.
关键字： JAK inhibitor; JAK inhibitor; generic development; GMP; DMF under preparati;
山东济坤生物制药有限公司是一家专注于药品、医疗器械研发、生产、贸易及委托定制服务（CRO/CMO/CDMO/CSO）为一体的高科技企业，拥有卓越的研发能力、完善的产业化基地和国际化的质量管理体系。公司始终把科技创新作为第一发展战略，深耕医药研发、创新医药生产、汇智医药服务，聚焦医药前沿领域，坚持创新发展策略，以市场需求为核心，以产品创新为先导，引入数字化项目管理系统、采用国际领先的自动化、智能化设备设施、推行精益化管理模式，秉承“健康与美丽同行”的美好愿景，以提高生命质量、赋能美丽人生为目标，加快科技创新，努力为客户提供高价值服务，持续助力人类健康事业蓬勃发展。
公司致力于打造拥有自主创新能力和国际竞争能力的仿制药、高端制剂、医疗器械及新药研发团队。通过学术交流、设立培养基地、联合创办实验室等方式，与中国药科大学、沈阳药科大学等多家国内外知名院校、科研单位建立了长期稳定的战略合作关系，不断聚合全球医药研发领域的科研、管理人才与资源，瞄准世界医药科技前沿，开展多渠道，多形式的科研攻关，形成了以权威机构和高科技领头人为主要成员的研发平台。打造了具有前瞻性、差异化的研发战略和丰富的产品管线储备。